```html

Capillary Hemangioma – Comprehensive Medical Guide

Overview

Capillary hemangioma, also known as a “strawberry mark” or infantile hemangioma when it appears in newborns, is a benign (non‑cancerous) tumor composed of tightly packed, tiny blood vessels (capillaries). These lesions are usually bright red, raised, and can appear anywhere on the skin or mucous membranes. While the majority arise in infancy, similar vascular proliferations can develop in children and, rarely, adults.

Who it affects: Approximately 4–5 % of infants are born with a capillary hemangioma. The condition is three to five times more common in girls than boys and is slightly more prevalent in Caucasian and Asian populations compared with African‑American infants. Most lesions appear within the first weeks of life, grow rapidly for several months, and then enter a slow involution phase.

Prevalence: In the United States, around 1 in 20 infants will develop a clinically significant capillary hemangioma that requires monitoring or treatment (CDC, 2022). In most cases the lesion is small and harmless, but up to 10 % of infants may need medical intervention because of functional impairment, ulceration, or cosmetic concerns (Mayo Clinic, 2023).

Symptoms

Capillary hemangiomas can vary widely in size, location, and behavior. Below is a comprehensive list of common and less‑common manifestations.

Typical skin findings

• Bright red, raised plaque – looks like a strawberry; often smooth to the touch.
• Flat red macule – may be mistaken for a birthmark; can later thicken.
• Rapid growth phase – lesion may double in size within weeks during the first 6–12 months.

Location‑specific symptoms

• Facial lesions – can involve eyelids, nose, or lips, potentially obstructing vision or feeding.
• Periorbital hemangioma – may cause astigmatism, amblyopia (“lazy eye”), or ptosis.
• Oral cavity – can interfere with swallowing, speech, or dental eruption.
• Airway (subglottic) hemangioma – presents with noisy breathing, stridor, or feeding difficulties.

Complications that produce symptoms

• Ulceration – painful open sore that may bleed or become infected.
• Bleeding – especially after trauma or during ulceration.
• Scarring – after ulceration or after the lesion involutes.
• Functional impairment – vision loss, hearing difficulties, airway obstruction, or feeding problems.

Causes and Risk Factors

The exact trigger for the abnormal proliferation of capillary endothelial cells is not fully understood, but several factors appear to increase risk.

Genetic and developmental factors

• Somatic mutations in the VEGF (vascular endothelial growth factor) pathway have been identified in many infantile hemangiomas (NIH, 2021).
• Prematurity – infants born before 37 weeks have a 2–3 × higher chance of developing hemangiomas.
• Low birth weight (< 2.5 kg) is independently associated with increased incidence.

Maternal and perinatal risk factors

• Maternal age > 35 years
• Multiple gestation (twins, triplets)
• Placental abnormalities (e.g., chorionic villus sampling, preeclampsia)
• Use of assisted reproductive technologies

Demographic factors

• Female sex (≈ 70 % of cases)
• Caucasian or Asian ancestry (higher reported rates than African‑American)

Diagnosis

Diagnosis is primarily clinical, based on visual inspection and history. However, certain situations require imaging or laboratory work.

Clinical examination

• Inspection of size, color, texture, and growth pattern.
• Assessment of functional impact (vision, breathing, feeding).
• Documentation with photographs for monitoring.

Imaging studies

• Ultrasound with Doppler – first‑line; shows high‑flow vascular channels.
• Magnetic Resonance Imaging (MRI) – indicated for deep or extensive lesions, especially near the orbit, airway, or brain.
• CT scan – rarely needed; useful for bony involvement.

Biopsy

Usually unnecessary because the lesion is benign and characteristic. A biopsy may be performed if the appearance is atypical or there is suspicion for a malignant vascular tumor (e.g., tufted angioma, Kaposi sarcoma).

Laboratory tests

Not routinely required, but a complete blood count (CBC) and coagulation profile may be ordered if there is ulceration, bleeding, or suspicion of associated syndromes (e.g., PHACE syndrome).

Treatment Options

Most capillary hemangiomas regress without intervention. Treatment is considered when the lesion threatens vision, airway, hearing, feeding, or causes ulceration, pain, or significant cosmetic concern.

Pharmacologic therapy

• Propranolol (beta‑blocker) – First‑line oral medication. Typical dose: 1–3 mg/kg/day divided BID. Works by vasoconstriction, inhibition of angiogenesis, and induction of apoptosis. Most effective when started during the proliferative phase (Cleveland Clinic, 2022).
• Topical timolol – 0.5 % solution applied twice daily for superficial lesions; useful when systemic therapy is contraindicated.
• Corticosteroids – Oral or intralesional; now largely replaced by propranolol but still used if beta‑blockers are contraindicated.
• Interferon‑α – Reserved for refractory cases; carries risk of neurologic toxicity.

Procedural interventions

• Laser therapy (pulsed dye laser) – Targets superficial vascular lesions, reduces redness, and aids ulcer healing.
• Intralesional corticosteroid injection – Directly reduces volume in localized lesions.
• Surgical excision – Considered for residual fibrofatty tissue after involution, or for deep lesions causing functional problems.
• Embolization – Rarely used for extensive airway hemangiomas that do not respond to medical therapy.

Supportive & lifestyle measures

• Gentle skin care; avoid trauma or friction.
• Keep ulcerated lesions clean with saline dressings.
• Maintain adequate nutrition; breast‑feeding is encouraged.
• Regular ophthalmology or ENT follow‑up for lesions near critical structures.

Living with Capillary Hemangioma

While most children outgrow these lesions, families can take practical steps to minimize discomfort and monitor progress.

• Track growth – Measure the lesion weekly during the first year; photograph at each visit.
• Protect from sun – UV exposure can darken the lesion; use a broad‑spectrum sunscreen (SPF 30+) on exposed areas.
• Skin hygiene – Use mild, fragrance‑free cleansers; pat dry, do not rub.
• Comfort for ulcerated lesions – Apply hydrocolloid dressings; discuss pain control with the pediatrician.
• Psychosocial support – Large facial lesions may affect self‑esteem; counseling or support groups can be beneficial.
• Follow‑up schedule – Typically every 1–3 months during rapid growth, then every 6–12 months until involution is complete.

Prevention

Because capillary hemangiomas arise from spontaneous vascular proliferation, there is no guaranteed way to prevent them. However, the following measures may lower risk or mitigate severity:

• Optimize prenatal care: control maternal hypertension, avoid smoking, and manage diabetes.
• Prevent preterm birth when possible through appropriate obstetric care.
• Early neonatal skin examinations allow prompt identification and monitoring.

Complications

If left untreated when indicated, capillary hemangiomas can lead to:

• Visual impairment – amblyopia, astigmatism, or retinal detachment from periorbital lesions.
• Airway obstruction – respiratory distress, stridor, or failure to thrive from subglottic hemangioma.
• Severe ulceration – infection, scarring, or chronic pain.
• Hearing loss – middle ear involvement can cause conductive hearing deficits.
• Psychological impact – disfigurement may affect social development.

When to Seek Emergency Care

References

• Mayo Clinic. “Infantile hemangioma.” 2023. https://www.mayoclinic.org/diseases-conditions/infantile-hemangioma
• Centers for Disease Control and Prevention (CDC). “Birth Defects and Hemangiomas.” 2022.
• National Institutes of Health (NIH). “Molecular Pathogenesis of Infantile Hemangioma.” 2021. PMC7075720
• Cleveland Clinic. “Capillary Hemangioma Treatment.” 2022.
• World Health Organization (WHO). “Classification of Vascular Anomalies.” 2020.

```